Icahn School of Medicine at Mount Sinai and The New York Academy of Medicine (NYAM) announced the formation of a new partnership to jointly study and address a number of significant health issues and policies that impact the lives of people who live in urban areas. NYAM is an historic and independent institution that has been advancing the health of people living in cities since its founding in 1847.
In February, CBS This Morning had a segment on Mount Sinai’s novel use of fruit flies to screen for personalized cancer drugs. Ross Cagan, PhD, Associate Dean of the Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, discussed how his laboratory replicates a patient’s tumor and implants it in a fruit fly. Then his team tests an arsenal of 840 drugs—all approved by the U.S. Food and Drug Administration for other uses—to see if they shrink the tumor.
“Philanthropy in an academic medical center such as the Mount Sinai Health System helps improve patient care and provides necessary funding for the innovative treatments that answer society’s pressing health care needs,” according to leaders of Mount Sinai, who recently appeared on a special edition of CNBC’s television show Squawk Box to discuss their support.
The most recent study from the Seaver Autism Center at Mount Sinai draws a possible link between the genetic abnormalities attributed to autism spectrum disorder (ASD), and dysregulation of the mechanism by which unused neural connections are pruned during development. This information builds upon prior discoveries at the Seaver Center, which identified three kinds of genetic mutations that are believed to contribute to autism risk: de novo mutations; recessive or X-linked mutations; and small chromosomal abnormalities.
Functional decline, measured as the loss of ability to accomplish activities of daily living, such as bathing and dressing, planning or cooking a meal, and paying bills, is the major symptom in individuals with Alzheimer’s disease and the primary source of caregiver burden. Yet, few studies have focused on ways to slow this functional decline.
In a recently published study in The Journal of the American Medical Association, researchers, co-led by an investigator from Icahn School of Medicine at Mount Sinai, reported that vitamin E, also known as alpha tocopherol, reduced functional decline in patients with mild-to-moderate Alzheimer’s disease.
Susan B. Bressman, MD, a leading researcher, clinician, and educator in movement disorders and neurological conditions, has been named a “National Physician of the Year” for clinical excellence by Castle Connolly Medical Ltd., publisher of the annual America’s Top Doctors® guides. Dr. Bressman is Chair of the Mirken Department of Neurology at Mount Sinai Beth Israel and Chair of Neurology at Mount Sinai Roosevelt and Mount Sinai St. Luke’s.
Virtual-reality simulation, designed to improve outcomes and reduce complications in patients undergoing brain surgery, is being pioneered at the Icahn School of Medicine at Mount Sinai as an innovative training tool for neurosurgery residents and as a program to help experienced surgeons advance their skill-sets.
Evan L. Flatow, MD, a world-renowned leader in shoulder surgery who has made many clinical, educational, and research contributions to the care of shoulder disorders, will assume the position of President of Mount Sinai Roosevelt after March 1.